GlobeNewswire by notified

Munich Re upscaling human rights due diligence using Verisk’s ESG risk analytics

Share

LONDON, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Munich Re, a leading global provider of reinsurance, primary insurance and insurance-related risk solutions, has selected Verisk’s global risk analytics business, Verisk Maplecroft, to help it enhance human rights due diligence across the entire enterprise.

Using Verisk Maplecroft’s world leading Human Rights Risk Indices, which identify exposure to 31 civil, political and labour rights risks at national and subnational levels in 198 countries, Munich Re will upscale its ability to undertake global operational risk assessments, alongside factoring the data into its underwriting and investment decisions.

 “Munich Re has always been committed to observe its duty of care on human rights along the value chain and has strived to prevent potential adverse impact on human rights arising from its business operations,” says Silke Jolowicz, Head of Sustainability at Munich Re. “To meet our strong internal requirements and the increasing legal obligations facing global business today we have decided to work with Verisk Maplecroft whose data will help us achieve these aims.”

Verisk Maplecroft has been measuring and analysing human rights risks for over 15 years. Its Human Rights Dataset is the only structured set of analytics covering the full range of rights the world over and is recognised as the benchmark for excellence in assessing these risks. The data has long been used by multinationals managing human rights risks in their operations and supply chains, and by asset managers and banks assessing and addressing their human rights risk exposure across complex global investment and lending portfolios. Adoption by insurers is the next step.

“As sustainability and ESG continue to quickly move more central into insurer’s strategic and operational thinking, we’re seeing increased attention from companies in the sector into how they can better manage human rights due diligence processes and wider ESG issues, such as climate change,” says Verisk Maplecroft President Matt Moshiri. “Munich Re is one of the first movers in this space and we are delighted to be working with them in their efforts.”

About Verisk Maplecroft

As organisations strive to understand and adapt to a fast-moving world, Verisk Maplecroft empowers them to put the environment, human rights and political risk at the heart of their decision-making. We do this by providing unparalleled intelligence on sustainability, resilience and ESG – stitching together these disparate issues into an interconnected global view, built upon objective insight and data. By thinking ‘big picture’ we capture what matters most to our partners; making positive outcomes possible in a time of change; helping people, business and societies become stronger; creating value with values. Verisk Maplecroft is a Verisk business (Nasdaq: VRSK).

For more information visit: www.maplecroft.com

About Verisk

Verisk (Nasdaq: VRSK) provides data-driven analytic insights and solutions for the insurance and energy industries. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk empowers customers to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global issues, including climate change and extreme events as well as political and ESG topics. With offices in more than 30 countries, Verisk consistently earns certification by Great Place to Work and fosters an inclusive culture where all team members feel they belong. For more, visit Verisk.com and the Verisk Newsroom.

About Munich Re

Munich Re is one of the world’s leading providers of reinsurance, primary insurance and insurance-related risk solutions. The Group consists of the reinsurance and ERGO business segments, as well as the asset manager MEAG. Munich Re is globally active and operates in all lines of the insurance business. Since it was founded in 1880, Munich Re has been known for its unrivalled risk-related expertise and its sound financial position. It offers customers financial protection when faced with exceptional levels of damage – from the 1906 San Francisco earthquake through Hurricane Ida in 2021. Munich Re possesses outstanding innovative strength, which enables it to also provide coverage for extraordinary risks such as rocket launches, renewable energies or cyber risks. The company is playing a key role in driving forward the digital transformation of the insurance industry, and in doing so has further expanded its ability to assess risks and the range of services that it offers. Its tailor-made solutions and close proximity to its customers make Munich Re one of the world’s most sought-after risk partners for businesses, institutions, and private individuals.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ING announces share buyback programme of up to €2.5 billion2.5.2024 07:03:00 CEST | Press release

ING announces share buyback programme of up to €2.5 billion ING announced today a share buyback programme under which it plans to repurchase ordinary shares of ING Groep N.V., for a maximum total amount of €2.5 billion. The purpose of the share buyback programme is to converge our CET1 ratio towards our target of around 12.5%. ING Group’s CET1 ratio was 14.8% at the end of the first quarter of 2024, which is well above the prevailing CET1 ratio requirement of 10.94%. The share buyback programme will have an impact of approximately 77 bps on our CET1 ratio. The programme will commence on 2 May 2024 and is expected to end no later than 29 October 2024. The ECB has approved the programme, which will be executed in compliance with the Market Abuse Regulation and within the limitations of the existing authority to acquire a maximum of 20% of the issued shares as granted by the general meeting of shareholders on 22 April 2024. ING has entered a non-discretionary arrangement with a financial

CEX.IO Launches Mastercard-branded Crypto Debit Card2.5.2024 07:00:00 CEST | Press release

The new product enables registered users in the EEA to make everyday payments with their crypto holdings, and integrates seamlessly with CEX.IO App. VILNIUS, May 02, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem working to bridge the worlds of crypto and traditional finance, announces the debut of CEX.IO Card, a debit card that empowers users to seamlessly spend their crypto assets on everyday purchases. This innovative product marks a pivotal step forward in CEX.IO’s mission to simplify crypto adoption, and bring the benefits of decentralized finance to the masses. The CEX.IO Card seamlessly integrates into users’ existing spending habits, allowing them to effortlessly make purchases with millions of merchants who accept Mastercard, in over 150 countries. Users can fund their cards via a variety of accessible methods, including bank transfers, as well as fiat and crypto deposits. In addition, they may set ranked priorities for their preferred methods, ensuring they always have a

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions2.5.2024 07:00:00 CEST | Press release

EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company’s website (www.ir.onwd.com) and the AFM's website (afm.nl). Imp

Biotalys Starts Field Trials for Second Biofungicide2.5.2024 07:00:00 CEST | Press release

Ghent, BELGIUM, May 02, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the initiation of field trials for BioFun-6, the company’s second biofungicide program under development on its AGROBODY technology platform. Kevin Helash, Chief Executive Officer of Biotalys,commented: “Moving BioFun-6 into the field is another important milestone for Biotalys, demonstrating our ability to advance a series of protein-based bioactive ingredients on our platform in concert. As our first product candidate, EVOCA™, progresses through the needed regulatory process and its commercial version EVOCA NG enters its final development stage with our partner Novonesis, we will continue to build our strong pipeline of biofungicides and bioinsecticides to help growers in their transition towards more sustainable practices.” BioFun-6 is a biofungicide targeting botrytis, powdery mil

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations2.5.2024 07:00:00 CEST | Press release

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a phase 3b clinical study conducted in close to real-life conditions7-10 Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain un

HiddenA line styled icon from Orion Icon Library.Eye